...
首页> 外文期刊>Journal of Medicinal Chemistry >Identification of (3R)-7-Hydroxy-N-(1S)-1-{[3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide as a Novel Potent and Selective Opioid κ Receptor Antagonist
【24h】

Identification of (3R)-7-Hydroxy-N-(1S)-1-{[3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide as a Novel Potent and Selective Opioid κ Receptor Antagonist

机译:(3R)-7-羟基-N-(1S)-1-{[[3R,4R)-4-(3-羟苯基)-3,4-二甲基-1-哌啶基]甲基} -2-甲基丙基)的鉴定-1,2,3,4-四氢-3-异喹啉甲酰胺作为新型有效的选择性阿片样物质κ受体拮抗剂

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

(3R)-7-Hydroxy-N-(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic) was identified as a potent and selective κopioid receptor antagonist. Structure-activity relationship (SAR) studies on JDTic analogues revealed that the 3R, 4R stereochemistry of the 3,4-dimethyl-4-(3-hydroxy-phenyl)piperidine core structure, the 3R attachment of the 7-hydroxy-1,2,3,4-tetrahydroiso-quinoline group, and the 1S configuration of the 2-methylpropyl (isopropyl) group were all important to its κ potency and selectivity. The results suggest that, like other κ opioid antagonists such as nor-BNI and GNTI, JDTic requires a second basic amino group to express potent and selective κ antagonist activity in the [~(35)S]GTPγS functional assay. However, unlike previously reported κ antagonists, JDTic also requires a second phenol group in rigid proximity to this second basic amino group. The potent and selective κ antagonist properties of JDTic can be rationalized using the "message-address" concept wherein the (3R,4R)-3,4-dimethyl-4-(hydroxyphenyl)piperidinyl group represents the message, and the basic amino and phenol group in the N substituent constitutes the address. It is interesting to note the structural commonality (an amino and phenol groups) in both the message and address components of JDTic. The unique structural features of JDTic will make this compound highly useful in further characterization of the κ receptor.
机译:(3R)-7-羟基-N-(1S)-1-{[((3R,4R)-4-(3-羟苯基)-3,4-二甲基-1-哌啶基]甲基} -2-甲基丙基)- 1,2,3,4-四氢-3-异喹啉羧酰胺(JDTic)被确定为有效且选择性的κ阿片受体拮抗剂。对JDTic类似物的结构活性关系(SAR)研究表明,3,4-二甲基-4-(3-羟基-苯基)哌啶核心结构的3R,4R立体化学,7-羟基-1的3R附着, 2,3,4-四氢异喹啉基团和2-甲基丙基(异丙基)基团的1S构型均对其κ效能和选择性很重要。结果表明,与其他κ阿片类拮抗剂(如nor-BNI和GNTI)一样,JDTic在[〜(35)S]GTPγS功能测定中需要第二个碱性氨基来表达有效和选择性的κ拮抗剂活性。但是,与先前报道的κ拮抗剂不同,JDTic还需要第二酚基团,该第二酚基团必须紧靠该第二碱性氨基基团。可以使用“消息地址”概念合理化JDTic的有效和选择性κ拮抗剂特性,其中(3R,4R)-3,4-二甲基-4-(羟苯基)哌啶基表示消息,碱性氨基和N取代基中的酚基构成地址。有趣的是,在JDTic的消息和地址组件中都注意到了结构上的共性(一个氨基和一个酚基)。 JDTic的独特结构特征将使该化合物在进一步表征κ受体方面非常有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号